Browse
Submit Data
Databases
API
Help

Dataset Information

15 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Efforts To Access the Potent Antitrypanosomal Marine Natural Product Janadolide: Synthesis of Des-tert-butyl Janadolide and Its Biological Evaluation.

ABSTRACT: To identify novel antitrypanosomal agents based on Janadolide, a potent macrocyclic polyketide-peptide hybrid, a macrolactonization strategy was explored. We prepared des-tert-butyl Janadolide and evaluated its antitrypanosomal activity. Our findings suggest that the tert-butyl group is necessary for the desired bioactivity.

SUBMITTER: Athawale PR

PROVIDER: S-EPMC6044843 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Publications

Efforts To Access the Potent Antitrypanosomal Marine Natural Product Janadolide: Synthesis of Des-tert-butyl Janadolide and Its Biological Evaluation.

Athawale Paresh R PR Jachak Gorakhnath R GR Shukla Anurag A Shanmugam Dhanasekaran D Reddy D Srinivasa DS

ACS omega 20180227 2

To identify novel antitrypanosomal agents based on Janadolide, a potent macrocyclic polyketide-peptide hybrid, a macrolactonization strategy was explored. We prepared des-tert-butyl Janadolide and evaluated its antitrypanosomal activity. Our findings suggest that the tert-butyl group is necessary for the desired bioactivity. ...[more]

PMID: 30023831

Similar Datasets

Potent in vitro and in vivo anticancer activities of des-methyl, des-amino pateamine A, a synthetic analogue of marine natural product pateamine A.

Project description:We report here that des-methyl, des-amino pateamine A (DMDA-PatA), a structurally simplified analogue of the marine natural product pateamine A, has potent antiproliferative activity against a wide variety of human cancer cell lines while showing relatively low cytotoxicity against nonproliferating, quiescent human fibroblasts. DMDA-PatA retains almost full in vitro potency in P-glycoprotein-overexpressing MES-SA/Dx5-Rx1 human uterine sarcoma cells that are significantly resistant to paclitaxel, suggesting that DMDA-PatA is not a substrate for P-glycoprotein-mediated drug efflux. Treatment of proliferating cells with DMDA-PatA leads to rapid shutdown of DNA synthesis in the S phase of the cell cycle. Cell-free studies show that DMDA-PatA directly inhibits DNA polymerases ? and ? in vitro albeit at concentrations considerably higher than those that inhibit cell proliferation. DMDA-PatA shows potent anticancer activity in several human cancer xenograft models in nude mice, including significant regressions observed in the LOX and MDA-MB-435 melanoma models. DMDA-PatA thus represents a promising natural product-based anticancer agent that warrants further investigation.

| S-EPMC3026899 | biostudies-literature

(R)-N-{2-tert-Butyl-2-[(R)-tert-butyl-sulfonamido]ethylidene}-tert-butane-sulfonamide.

Project description:The title compound, C(14)H(30)N(2)O(2)S(2), is the product of the monoaddition reaction of tert-butyl magnesium chloride with bis-[(R)-N-tert-butanesulfinyl]ethanediimine. There are two almost identical mol-ecules in the asymmetric unit, the mol-ecular conformation of which is stabilized by an intra-molecular N-H?N hydrogen bond.

| S-EPMC2959383 | biostudies-literature

4-tert-Butyl-pyridinium triiodide-4-tert-butyl-pyridine (1/1).

Project description:The title compound, C(9)H(14)N(+)·I(3) (-)·C(9)H(13)N, consists of monoprotonated 4-tert-butyl-pyridinium cations and triiodide anions. The triiodide ion has near-symmetric linear geometry, with bond lengths of 2.9105?(4)?Å (I-I) and a bond angle of 177.55?(3)° (I-I-I). For this room-temperature structure, the butyl group on the pyridine ring is disordered and has been treated as a rigid rotator, modeled in three separate positions with 1/3, 1/3, 1/3 occupancies. The cations assemble into dimeric forms by way of N-H?N hydrogen bonds.

| S-EPMC3051785 | biostudies-literature

tert-Butyl-aminium phosphite.

Project description:In the title compound, C(4)H(12)N(+)·H(2)PO(3) (-), the components are linked by inter-molecular N-H?O and O-H?O hydrogen bonds, resulting in a two-dimensional framework.

| S-EPMC2968602 | biostudies-literature

1-(4-tert-Butyl-benz-yl)-2-(4-tert-butyl-phen-yl)-1H-benzimidazole.

Project description:In the mol-ecule of the title compound, C(28)H(32)N(2), the benzimidazole ring system is almost planar [maximum deviation = 0.0221 (15) Å] and forms dihedral angles of 85.86 (4) and 32.09 (6)° with the benzene rings. In the crystal structure, mol-ecules are linked into chains running parallel to the a axis by inter-molecular C-H⋯N hydrogen bonds. The methyl groups of a tert-butyl group are rotationally disordered over two positions with refined site-occupancy factors of 0.636 (4) and 0.364 (4).

| S-EPMC2971974 | biostudies-literature

tert-Butyl-dimethyl-silanol hemihydrate.

Project description:The crystal structure of the title compound, C(6)H(16)OSi·0.5H(2)O, reveals an asymmetric unit containing two mol-ecules of the silanol and a single water mol-ecule. There is evidence of hydrogen bonding between the three mol-ecules in the asymmetric unit. The H atoms of the silanol OH groups and the water H atoms are each disordered equally over two positions.

| S-EPMC2961358 | biostudies-literature

Metabolically Stable tert-Butyl Replacement.

Project description:Susceptibility to metabolism is a common issue with the tert-butyl group on compounds of medicinal interest. We demonstrate an approach of removing all the fully sp(3) C-Hs from a tert-butyl group: replacing some C-Hs with C-Fs and increasing the s-character of the remaining C-Hs. This approach gave a trifluoromethylcyclopropyl group, which increased metabolic stability. Trifluoromethylcyclopropyl-containing analogues had consistently higher metabolic stability in vitro and in vivo compared to their tert-butyl-containing counterparts.

| S-EPMC4027455 | biostudies-literature

N-tert-Butyl-3-mesitylpropanamide.

Project description:In the title compound, C(16)H(25)NO, the N-tert-butyl-propanamide fragment is essentially planar, with the exception of two C atoms of the tert-butyl group (r.m.s. deviation = 0.005?Å), forming a dihedral angle of 84.09?(10)° with the plane of the mesityl fragment (r.m.s. deviation = 0.002?Å). The crystal packing is stabilized by an inter-molecular N-H?O hydrogen bond, which links the mol-ecules into chains with graph-set notation C(4) running parallel to the c axis.

| S-EPMC3120507 | biostudies-literature

4-tert-Butyl-pyridinium picrate.

Project description:In the title compound, C(9)H(14)N(+)·C(6)H(2)N(3)O(7) (-), the three nitro groups of the picrate anion are twisted out of the plane of the attached benzene ring; the dihedral angles are 32.8 (2), 10.5 (4) and 12.3 (4)°. The pyridinium cations and picrate anions are linked via bifurcated N-H⋯(O,O) hydrogen bonds. The ionic pairs are linked into a ribbon-like structure along [101] by C-H⋯O hydrogen bonds.

| S-EPMC2983922 | biostudies-literature

Potent antitrypanosomal triterpenoid saponins from Mussaenda luteola.

Project description:Five new triterpenoid saponins, heinsiagenin A 3-O-[?-l-rhamnopyranosyl-(1?2)-?-d-glucopyranosyl-(1?2)]-?-d-glucopyranoside (1), heinsiagenin A 3-O-[?-l-rhamnopyranosyl-(1?2)-?-d-glucopyranosyl-(1?2)]-[?-d-glucopyranosyl-(1?4)]-?-d-glucopyranoside (2), 2?-hydroxyheinsiagenin A 3-O-[?-l-rhamnopyranosyl-(1?2)-?-d-glucopyranosyl-(1?2)]-?-d-glucopyranoside (3), 2?-hydroxyheinsiagenin A 3-O-[?-d-glucopyranosyl-(1?2)]-[?-d-glucopyranosyl-(1?4)]-?-d-glucopyranoside (4) and N-(2S, 3R, 4R-3-methyl-4-pentanolid-2-yl)-18-hydroxylanosta-8 (9), 22E, 24E-trien-27-amide-3-O-[?-l-rhamnopyranosyl-(1?2)-?-d-glucopyranosyl-(1?2)]-[?-d-glucopyranosyl-(1?4)]-?-d-glucopyranoside (5) were isolated from the aerial parts of Mussaenda luteola Delile (Rubiaceae). Structural elucidation was based on the analysis of spectroscopic data (1D and 2D NMR) and HR-ESI-MS. Compound 1 showed potent antitrypanosomal activity with an IC50 value of 8.80?M. Compounds 2-4 showed highly potent antitrypanosomal activity with IC50 values ranging between (2.57-2.84?M) and IC90 values ranging between (3.36-4.35?M), which are 5 fold greater than the positive control DFMO (IC50 and IC90 values of 13.06 and 28.99?M, respectively). Compounds 1 and 2 showed moderate affinity to ?-opioid receptors with Ki values of 9.936?M and 0.872?M, respectively compared to a Ki value of 1.958nM for the positive control, naloxone HCl.

| S-EPMC4883117 | biostudies-literature